Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.38 |
| ▸ | AKT1 | P31749 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | AKT2 | P31751 | 4/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21036381 | 1.00 | LRRK2 (0.38) | LRRK2AKT1JAK3AKT2HTR2A | |
| SCHEMBL21036384 | 1.00 | LRRK2 (0.38) | LRRK2AKT1JAK3AKT2HTR2A | |
| Hydrochloric Acid SCHEMBL21003115 | 0.99 | LRRK2 (0.38) | LRRK2AKT1JAK3AKT2HTR2A | |
| Hydrochloric Acid SCHEMBL21003252 | 0.99 | LRRK2 (0.38) | LRRK2AKT1JAK3AKT2HTR2A | |
| Hydrochloric Acid SCHEMBL21003114 | 0.99 | LRRK2 (0.38) | LRRK2AKT1JAK3AKT2HTR2A | |
| SCHEMBL21003147 | 0.90 | CYP1A2 (0.33) | HTR2AHTR2CHTR2BCYP1A2PRKDC | |
| SCHEMBL21036396 | 0.80 | HTR2C (0.42) | LRRK2JAK3AKT2HTR2AHTR2C | |
| SCHEMBL21319813 | 0.80 | DRD2 (0.45) | HTR2C | |
| SCHEMBL21005165 | 0.77 | HTR2C (0.40) | JAK3AKT2HTR2AHTR2CHTR2B | |
| SCHEMBL4083552 | 0.76 | HRH1 (0.45) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3717488-B1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | LRRK2 1757/4885AKT1 460/4885JAK3 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.